The role of the new antiaromatase agents in the endocrine treatment of breast cancer;Der stellenwert von aromatasehemmern der dritten generation in der endokrinen therapie des mammakarzinoms - Zeit zum umdenken?

Geburtshilfe und Frauenheilkunde

Volumn 62, Issue 1, 2002, Pages 15-21

  Huober, J ^a   Wagner, U ^a   Wallwiener, D ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; FORMESTANE; GOSERELIN; LETROZOLE; MEGESTROL ACETATE; PLACEBO; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HORMONE SENSITIVITY; HUMAN; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0036172239     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-20278     Document Type: Review

References (27)

1. Tamoxifen vs. aminoglutethimide in breast cancer patients previously treated with adjuvant tamoxifen. Preliminary results of a multicentric comparative study
2. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group (TARGET) efficacy and tolerability study
3. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer
4. Anastrozole arimidex versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women - Combined analysis from two identically designed multicenter trials
5. Anastrozole versus megestrolacetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on the combined analysis of data from two mature phase III trials
6. Efficacy of and tolerance to exemestane versus tamoxifen in 1st-line hormone therapy of postmenopausal metastatic breast cancer patients: A European Organisation for the Research and Treatment of Cancer phase-II trial with Pharmacia and Upjohn
7. Letrozol as primary medical therapy for local advanced and large operable breast cancer
8. Arimidex as neoadjuvant therapy causes large reductions in tumor volume in postmenopausal women with large operable breast cancer
9. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
10. Second generation aromatase inhibitors - 4-Hydroxyandrostenedione
11. Tamoxifen for early breast cancer: An overview of the randomised trials
12. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2 positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial
13. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial
14. Wirkungsweise und stellenwert der neuen aromatasehemmer in der therapie des mammakarzinoms
15. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
16. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with breast cancer: Results of a phase III randomized double-blind trial
17. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study
18. Hormonal therapy of breast cancer
19. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial
20. Anastrozole vs. tamoxifen in hormone dependent advanced breast cancer. A phase II randomized trial
21. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the international letrozole breast cancer group
22. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
23. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
24. Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer
25. Neoadjuvant treatment of postmenopausal breast cancer patients with letrozole (Femara®): A randomized study versus tamoxifen
26. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer
27. Efficacy of tamoxifen following arimidex (anastrozole) as first-line treatment for advanced breast cancer in postmenopausal women